Top Medical News
Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis
20 hours ago
In the treatment of radiographic axial spondyloarthritis (r-axSpA), the 2-year incidence of spinal radiographic progression is low and not different between secukinumab and adalimumab biosimilar, as shown in the phase IIIb study SURPASS study.
SGLT2 inhibitors a promising gout medication in T2D
Jairia Dela Cruz, Yesterday
The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.
Stair climbing difficulty tied to higher death risk in adults with knee OA
The risk of all-cause mortality appears to be elevated in adults with or at high risk for knee osteoarthritis (OR) who have difficulty climbing stairs or who seldom use the stairs.
Lower VTE risk seen in atopic dermatitis vs other inflammatory diseases
Stephen Padilla, 2 days ago
Atopic dermatitis (AD) does not seem to induce an increase in the risk of venous thromboembolism (VTE) when considering underlying risk factors, suggests a study. Moreover, patients with AD show a lower VTE risk than those with rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).
What are the risk factors for severe infections in hospitalized SLE patients?
5 days ago
Among hospitalized patients with systemic lupus erythematosus (SLE), factors such as low immunoglobulin, anti-dsDNA antibody positivity, and cyclophosphamide use contribute to an increased risk of recurrent severe infections, according to a study.
Progressive resistance training not superior to neuromuscular exercise for hip OA
17 Apr 2024
Progressive resistant training (PRT) does not seem to work better than neuromuscular exercise (NEMEX) for easing hip pain and improving functional performance or hip-related quality of life (QoL) in patients with hip osteoarthritis (OA), reports a recent study.
Patients with Takayasu arteritis at risk for aneurysmal disease
13 Apr 2024
Several patients with Takayasu arteritis (TA) have been shown to have aneurysmal disease, reveals a recent study.
Special Reports
AZD7442 (tixagevimab–cilgavimab) prevents COVID-19 in high-risk populations
Dr. Leong Hoe Nam, Dr. Behram Ali Khan, Dr. See Hui Ti, Dr. Yoon Kam Hon, 12 Oct 2022

Though most COVID-19 safe management measures have been lifted in Singapore, the pandemic continues to adversely impact the lives of immunocompromised patients at high risk of severe infection. 

“It has been an absolute misery for these patients and their families,” said Dr Leong Hoe Nam, Infectious Disease Specialist at Mount Elizabeth Novena Hospital, Singapore. “The virus is an unseen enemy that may strike unexpectedly. The strike may kill, or if not, maim the individual. Patients isolate themselves for fear of getting infected while their family members fear bringing the illness back home.” 

Immunocompromised patients are those with suppressed immunity resulting from health conditions, including solid organ and haematological cancers, end-stage kidney and liver disease, organ or bone marrow transplants, and immune-mediated inflammatory diseases such as rheumatoid arthritis, or those on active treatment with immunosuppressive medications. [Expert Rev Vaccines 2022;1-17; BMJ 2021;374:n2098]

Managing comorbidities in rheumatoid arthritis in the new decade
Prof. Peter Taylor, Prof. Christopher Edwards, Dr. Lian Tsui Yee, 03 Nov 2021
Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.
Conference Reports
Real-world data back CV safety of JAK inhibitors
Audrey Abella, 28 Jun 2023
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Uricase-based combo therapy promising for refractory gout
Elvira Manzano, 28 Jun 2023
Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.
SGLT2 inhibitors score big, this time in gout
Elvira Manzano, 22 Jun 2023
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
Novel drug STRIDES in the right direction for knee OA
Audrey Abella, 21 Jun 2023
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Dazodalibep reduces Sjögren’s syndrome-related symptoms
Elaine Soliven, 21 Jun 2023
Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.
Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users
Jairia Dela Cruz, 20 Jun 2023
In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.
Artificial intelligence, if used correctly can empower the world of medicine.
Stephen Padilla, 20 Jun 2023
It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.